Literature DB >> 6496744

Isolation of calcium oxalate crystal growth inhibitor from rat kidney and urine.

Y Nakagawa, V Abram, F L Coe.   

Abstract

Glycoproteins that slow the growth rate of calcium oxalate monohydrate crystals were purified from rat kidney homogenate and urine by selective heat denaturation (for rat kidney homogenate), DEAE-cellulose column chromatography, and gel permeation column chromatography. Both kidney and urine inhibitors were glycoproteins with an apparent mol wt of 1.4 X 10(4), as determined by high-performance liquid chromatography. They contained gamma-carboxyglutamic acid and a high percentage of aspartic acid and glutamic acid but had few aromatic amino acid residues. Both inhibitors contained fucose, mannose, glucose, galactose, glucosamine, galactosamine, and N-acetylneuraminic acid but no glucuronic acid. Kinetic studies suggest that purified inhibitors bind to calcium oxalate monohydrate seed crystals according to a Langmuir adsorption isotherm with similar dissociation constants of 14 X 10(-8)M for rat urine inhibitor and 8.7 X 10(-8) M for rat kidney inhibitor. The isolation of similar glycoproteins from kidney and urine suggests that urinary crystal growth inhibitor may be produced in the kidneys.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6496744     DOI: 10.1152/ajprenal.1984.247.5.F765

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  Synergism between the brushite and hydroxyapatite urinary crystallization inhibitors.

Authors:  Antonia Costa-Bauzá; Catalina Barceló; Juan Perelló; Felix Grases
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

Review 2.  Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation.

Authors:  R L Ryall
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 3.  Glycosaminoglycans, proteins, and stone formation: adult themes and child's play.

Authors:  R L Ryall
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

4.  Urine glycoprotein crystal growth inhibitors. Evidence for a molecular abnormality in calcium oxalate nephrolithiasis.

Authors:  Y Nakagawa; V Abram; J H Parks; H S Lau; J K Kawooya; F L Coe
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

5.  The effect of warfarin on urine calcium oxalate crystal growth inhibition and urinary excretion of calcium and nephrocalcin.

Authors:  E M Worcester; J L Sebastian; J G Hiatt; A M Beshensky; J A Sadowski
Journal:  Calcif Tissue Int       Date:  1993-10       Impact factor: 4.333

6.  Characterization of calcium-binding sites in the kidney stone inhibitor glycoprotein nephrocalcin with vanadyl ions: electron paramagnetic resonance and electron nuclear double resonance spectroscopy.

Authors:  D Mustafi; Y Nakagawa
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

7.  Isolation and purification of a new glycoprotein from human urine inhibiting calcium oxalate crystallization.

Authors:  F Atmani; B Lacour; T Drüeke; M Daudon
Journal:  Urol Res       Date:  1993-01

8.  Isolation from human calcium oxalate renal stones of nephrocalcin, a glycoprotein inhibitor of calcium oxalate crystal growth. Evidence that nephrocalcin from patients with calcium oxalate nephrolithiasis is deficient in gamma-carboxyglutamic acid.

Authors:  Y Nakagawa; M Ahmed; S L Hall; S Deganello; F L Coe
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.